Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-55136 Skye Bioscience, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |---------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of regis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of regi ...

财务表现 - 公司2022年净亏损为19,481,602美元，相比2021年的8,522,182美元有所增加[175] - 截至2022年12月31日，公司累计亏损为66,737,765美元，经营活动现金流为-12,744,072美元[175] - 2022年12月31日，公司持有无限制现金为1,244,527美元，相比2021年的8,983,007美元有所减少[175] - 2022年研发费用为6,011,805美元，较2021年的2,931,437美元增加了3,080,368美元，增幅为105%[193] - 2022年研发费用增加主要由于合同研发活动增加，包括2,348,534美元用于制造SBI-100 OE的临床试验材料[193] - 2022年一般和管理费用为6,094,617美元，较2021年的4,916,277美元增加了1,178,340美元，增幅为24%[194] - 2022年一般和管理费用增加主要由于员工工资和董事会费用增加746,952美元，以及专业和法律费用增加732,529美元[194] - 2022年法律 contingency 估计为6,205,310美元，与Cunning Lawsuit相关[196] - 2022年其他费用净额为1,163,129美元，主要由于利息费用和收购相关的清算成本[197] - 2022年利息费用减少104,026美元，下降14%，主要由于修订信贷协议下的平均未偿还本金余额较低[197] - 2022年衍生负债公允价值减少80,894美元，下降382%[197] - 2022年利息收入增加19,008美元，增长633,600%[197] - 2022年PPP贷款豁免收益为117,953美元，2021年为(100)%[197] - 2022年融资费用为120,228美元，2021年为0美元[197] - 2022年清算成本为456,508美元，2021年为0美元[197] - 截至2022年12月31日，公司累计亏损66,737,765美元，股东权益赤字3,008,054美元，营运资本赤字3,175,408美元[200] - 2022年经营活动现金流量为(12,744,072)美元，主要用于研发活动和一般行政活动[204] - 2022年投资活动现金流量为5,214,395美元，主要来自收购的现金收益[205] 临床试验进展 - 公司预计2023年中期开始SBI-100 OE的Phase 2临床试验[172] - 公司于2022年12月获得FDA对SBI-100 OE的IND批准，允许在美国进行临床研究[172] - 公司于2022年9月完成Phase 1临床试验材料的制造，并预计2023年上半年完成Phase 1试验的招募[170] - 公司预计2023年第四季度报告Phase 1临床试验的最终数据[166] 收购与资产处置 - 公司于2022年11月10日完成对EHT的收购，每1股EHT股票兑换1.95股公司股票[168] - 公司从VDL的出售中获得5,547,000美元，用于资助Phase 1和Phase 2临床试验[168] - 公司计划在未来一年内出售VDL房地产资产、Health Canada许可证及相关知识产权[188] 税务与激励 - 公司通过澳大利亚政府的研究和开发税收激励计划，可获得48.5%的退税，前提是年营业额低于2000万美元[170] 会计与财务处理 - 公司使用Black-Scholes估值方法估计股票期权的授予日公允价值，假设包括历史股价波动、简化方法的预期期限、基于美国国债的预期无风险利率以及未来无股息支付[183] - 公司根据ASC 815和ASC 470-20处理具有嵌入式转换特征的混合合同，将转换选项作为独立衍生金融工具处理，并在每个报告日期按公允价值记录[179] - 公司根据ASC 480-10评估混合工具的会计处理，符合特定条件的金融工具被分类为负债，并在每个资产负债表日期按公允价值重新计量[181] - 公司根据ASC 718处理负债分类的股票期权奖励，初始按公允价值确认，并在每个报告日期重新计量，变化计入股票补偿费用[183]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of regis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of regi ...

FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from __________ to __________ Commission File Number: 000-55136 Skye Bioscience, Inc. | Title of each class: | Name of each exchange on which registered: | | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Skye Bioscience, Inc. _____________________________________________________________ (Exact name of ...